Suppr超能文献

78 例肺肉瘤样癌患者外科治疗的临床分析。

Clinical analysis of 78 pulmonary sarcomatoid carcinomas with surgical treatment.

机构信息

Department of Medical Oncology, Tianjin Medical University General Hospital, Tianjin, China.

Department of Lung Cancer, Tianjin Lung Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.

出版信息

J Int Med Res. 2022 Oct;50(10):3000605221128092. doi: 10.1177/03000605221128092.

Abstract

OBJECTIVE

To evaluate clinical factors influencing the postoperative pulmonary sarcomatoid carcinoma (PSCs) prognosis.

METHODS

We retrospectively evaluated patients with PSCs treated from October 2012 to October 2017. Kaplan-Meier survival curves were calculated using univariable analysis (log-rank test). Univariable/multivariable Cox regression analysis was also performed.

RESULTS

Mixed PSCs were most common (64.10%). Pure PSCs occurred more often with large tumors compared with mixed PSCs. Patients with vs without pleural retraction, respectively, had significantly worse overall survival (OS; 16 vs 23 months) and disease-free survival (DFS; 11 vs 20 months), and patients with airway dissemination had significantly shorter OS (14 vs 21 months) and DFS (11 vs 20 months). Patients with PSC with an adenocarcinoma component had favorable OS. Airway dissemination, pleural retraction, metastatic mediastinal lymph node (LN) number, and pathological tumor-node-metastasis (pTNM) stage were risk factors for short OS. Neither adjuvant chemotherapy nor adjuvant radiotherapy provided a survival advantage. Airway dissemination was an independent prognostic factor (odds ratio, 1.87; 95% confidence interval, 1.04-3.36).

CONCLUSION

Pure PSCs were more likely with large tumors compared with mixed PSCs. Airway dissemination, pleural retraction, and metastatic mediastinal LN number were associated with OS. Airway dissemination was an independent prognostic factor.

摘要

目的

评估影响肺肉瘤样癌(PSCs)术后预后的临床因素。

方法

我们回顾性评估了 2012 年 10 月至 2017 年 10 月期间接受治疗的 PSCs 患者。使用单变量分析(对数秩检验)计算 Kaplan-Meier 生存曲线。还进行了单变量/多变量 Cox 回归分析。

结果

混合 PSCs 最常见(64.10%)。与混合 PSCs 相比,纯 PSCs 更常发生于大肿瘤患者。与无胸膜回缩的患者相比,有胸膜回缩的患者总生存期(OS;16 个月 vs 23 个月)和无病生存期(DFS;11 个月 vs 20 个月)明显更差,气道播散的患者 OS(14 个月 vs 21 个月)和 DFS(11 个月 vs 20 个月)明显更短。具有腺癌成分的 PSC 患者 OS 良好。气道播散、胸膜回缩、转移性纵隔淋巴结(LN)数量和病理肿瘤-淋巴结-转移(pTNM)分期是 OS 较短的危险因素。辅助化疗和辅助放疗均不能带来生存优势。气道播散是独立的预后因素(优势比,1.87;95%置信区间,1.04-3.36)。

结论

与混合 PSCs 相比,纯 PSCs 更可能发生于大肿瘤患者。气道播散、胸膜回缩和转移性纵隔 LN 数量与 OS 相关。气道播散是独立的预后因素。

相似文献

2
[Postoperative survival analysis of patients with stage Ⅲ-pN2 non-small cell lung cancer].Ⅲ期-pN2非小细胞肺癌患者的术后生存分析
Zhonghua Zhong Liu Za Zhi. 2018 Oct 23;40(10):782-786. doi: 10.3760/cma.j.issn.0253-3766.2018.10.011.

本文引用的文献

2
Pulmonary sarcomatoid carcinoma: progress, treatment and expectations.肺肉瘤样癌:进展、治疗与展望。
Ther Adv Med Oncol. 2020 Aug 25;12:1758835920950207. doi: 10.1177/1758835920950207. eCollection 2020.
7
Pulmonary Sarcomatoid Carcinomas: A Review.肺肉瘤样癌:综述。
Adv Anat Pathol. 2018 Sep;25(5):304-313. doi: 10.1097/PAP.0000000000000202.
8
Sarcomatoid Carcinoma of the Lung: The Mayo Clinic Experience in 127 Patients.肺肉瘤样癌:梅奥诊所 127 例患者的经验。
Clin Lung Cancer. 2018 May;19(3):e323-e333. doi: 10.1016/j.cllc.2017.12.008. Epub 2017 Dec 21.
9
Pulmonary sarcomatoid carcinoma: University of Cincinnati experience.肺肉瘤样癌:辛辛那提大学的经验
Oncotarget. 2017 Dec 18;9(3):4102-4108. doi: 10.18632/oncotarget.23468. eCollection 2018 Jan 9.
10
Spread through air spaces (STAS): a comprehensive update.通过气腔播散(STAS):全面更新
Transl Lung Cancer Res. 2017 Oct;6(5):501-507. doi: 10.21037/tlcr.2017.06.08.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验